Endpoints News
Lilly, Boehringer cut German investments Read in browser
Endpoints News
Thank you for reading, dupa dupackia!
basic
UPGRADE
Thursday
4 June, 2026
The Endpoints 100: Despite all the turmoil, biotech is having a moment
A year ago, biotech was in its bleakest stretch in a decade. Now IPOs are rebounding and China deals are heating up. John Carroll and a panel of industry leaders dig into the latest Endpoints 100 results and uncover what’s next for the sector.
top stories
1. Mammalian hair, roof leaks: Novo's Catalent site in Indiana under FDA scrutiny once again
2. Germany’s health-spending plan has consequences as Lilly, Boehringer scale back
3. Hikma to funnel $267M to Ohio; Cingulate gets CRL for ADHD drug 
4. Exclusive: Bipartisan group of lawmakers unveil new bill to restrict China biotech
5. Supreme Court sides with Hikma in 'skinny label' case
6. Lilly gives hospitals deadline to comply with 340B claims data policy
Anna Brown
.

It appears that issues at Novo Nordisk's Catalent site in Indiana are still ongoing, with a re-inspection flagging mammalian hair in products and a leaky roof. Check out the details below.

.
Anna Brown
Biopharma Breaking News Reporter, Endpoints News
1
by Anna Brown

No­vo Nordisk’s trou­bled fac­to­ry in In­di­ana that it got from Catal­ent con­tin­ues to face con­t­a­m­i­na­tion is­sues, with a re-in­spec­tion in April find­ing mam­malian hair in...

Read full story
2
by Ayisha Sharma

Back­lash is brew­ing against a sweep­ing over­haul of Ger­many’s health in­sur­ance sys­tem as Eli Lil­ly and Boehringer In­gel­heim slash in­vest­ment in the coun­try.

The drug­mak­er­s'...

Read full story
3
by Anna Brown

Plus, news about West Phar­ma­ceu­ti­cal, Stal­ler­genes Greer and Curi­um:

🏭 Hik­ma’s US ex­pan­sion: The gener­ic drug­mak­er is in­vest­ing$267 mil­lion in Ohio. Its ex­ist­ing fac­to­ry...

Read full story
Rep. John Moolenaar (R-MI) (Lenin Nolly/Sipa USA/Sipa via AP Images)
4
by Max Bayer

A bi­par­ti­san group of Michi­gan law­mak­ers re­leased a new bill that could great­ly sti­fle the boom­ing cross-bor­der deals spree be­tween Chi­nese and Amer­i­can biotechs.

Rep...

Read full story
5
by Nicole DeFeudis

The Supreme Court has unan­i­mous­ly sided with Hik­ma Phar­ma­ceu­ti­cals and its “skin­ny la­bel” ver­sion of a pre­scrip­tion-strength fish oil pill in a case that was...

Read full story
6
by Nicole DeFeudis

Eli Lil­ly is giv­ing a group of hos­pi­tals five days to com­ply with its new claims da­ta pol­i­cy or risk los­ing their 340B dis­counts.

Some...

Read full story
Endpoints News
2029 Becker Drive; Lawrence, Kansas 66047 USA Privacy and deletion: help@endpointsnews.com
web twitter linkedin